Back to search results

Anti-inflammatory Diet for Systemic Lupus Erythematosus (SLE)

This study is looking at how an anti-inflammatory diet affects people with Systemic Lupus Erythematosus (SLE), an autoimmune disease. Researchers want to see if this diet can help reduce pain and fatigue. You might be able to join if you are an adult with SLE, meet specific classification criteria, are currently taking Cellcept or Myfortic for at least three months, and have a certain level of pain interference. The study will measure changes in your pain and fatigue levels after six weeks on the diet. The goal is to understand how diet might impact lupus and potentially lead to new ways to help manage the condition. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 36 participants. It is designed to explore the short-term effects of dietary changes.
What's involved
Participants will follow an anti-inflammatory diet for 6 weeks. Blood and stool samples will be collected and analyzed.
Compensation
Not stated in the trial record.
Follow-up
The primary outcomes are measured at 6 weeks after starting the diet.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07713940

Effect of Anti-inflammatory Diet in Systemic Lupus Erythematous

Recruiting
NAAges 18+InterventionalTreatment
University of California, San Diego
~36 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:anti-inflammatory diet

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
PROMIS pain interference
Measured over 6 weeks
+1 more outcome measured

Conditions

Systemic Lupus Erthematosus (SLE)

Explore related trials

Systemic Lupus Erythematosus

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Monica Guma, MD, PhD · PRINCIPAL_INVESTIGATOR · UC San Diego

Who to contact

Monica Guma, MD, PhD
[email protected]
858-822-6523
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

patients who meet the 2019 EULAR/ACR Classification Criteria for SLE
patients who are on Cellcept or Myfortic for at least 3 months prior to screening
patients with a score of ≥55 on the Patient Reported Outcomes Measurement Information System (PROMIS) Pain interference scale.

Exclusion

pregnant or lactating patients,
patients with food allergy
patients on antibiotics within 4 weeks of the screening
patients that change the SLE therapy during the length of the study (12 weeks).

What this trial measures

  • PROMIS pain interference6 weeks

    PROMIS Pain Interference: Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference. Scores are typically reported as T-scores ranging from approximately 20 to 80 (theoretical range varies by item bank). Higher scores indicate worse outcomes, reflecting greater pain interference with daily activities.

  • PROMIS fatigue6 weeks

    PROMIS Fatigue: Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue. Scores are typically reported as T-scores ranging from approximately 20 to 80. Higher scores indicate worse outcomes, reflecting greater fatigue.